GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Other Financing

Capricor Therapeutics (STU:4LN2) Other Financing : €0.42 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics Other Financing?

Capricor Therapeutics's Other Financing for the three months ended in Dec. 2024 was €0.24 Mil.

Capricor Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was €0.42 Mil.

Capricor Therapeutics Other Financing Historical Data

The historical data trend for Capricor Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Other Financing Chart

Capricor Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.70 0.05 0.07 0.06 0.43

Capricor Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.08 0.11 0.24

Capricor Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » Other Financing
Comparable Companies
CRMD GHRS BCYC KROS NAGE ARVN TRVI ABUS ANAB IMTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CAPR:USA 4LN2:Germany
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Website
https://www.capricor.com
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Headlines

No Headlines